Literature DB >> 16162308

Treatment options for chronic cholestasis in infancy and childhood.

Vicky Lee Ng1, William F Balistreri.   

Abstract

Altered bile flow physiology leads to many complications commonly seen in patients with cholestatic liver disease, regardless of the etiology. For each individual patient, a coordinated and effective treatment strategy must address the presence and the severity spectrum of malabsorption, malnutrition, vitamin and micronutrient deficiencies, pruritus, xanthomata, ascites, and liver failure, which are attributed directly or indirectly to diminished bile flow. An aggressive approach to maximizing the nutritional status of the child is vital to ensure optimal growth and development. Protein-calorie and/or fat supplementation is best discussed early. Decreasing the percentage of dietary long-chain triglycerides, providing medium-chain triglycerides, and ensuring adequate essential fatty acid and adequate protein intake may be helpful. Fat-soluble vitamin (A, D, E, and K) levels and micronutrient levels must be carefully and serially monitored and supplemented as necessary. Because the mechanisms that mediate pruritus of cholestasis remain to be determined, the use of empirical therapies continues to be standard practice. Ursodeoxycholic acid may ameliorate pruritus. Antihistamines and rifampicin may also provide temporary relief for some children. Based on the evidence that increased central opioidergic tone is present in chronic cholestasis, the use of opiate antagonists is promising but has not been evaluated in children. Selected patients with refractory pruritus that have failed maximal medical therapy have benefited from partial external biliary diversion. Ongoing dialogue with the family regarding the indications for liver transplantation is reasonable. Optimization and adherence with the pretransplant medical management enhance the chances for a successful outcome from liver transplantation. Specific to the pediatric patient, optimizing growth, development and nutrition, minimizing discomfort and disability, and aiding the child and family in coping with the stress, social, and emotional effects of chronic liver disease remain paramount.

Entities:  

Year:  2005        PMID: 16162308     DOI: 10.1007/s11938-005-0045-5

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  47 in total

1.  Resistance to the growth-promoting and metabolic effects of growth hormone in children with chronic liver disease.

Authors:  J C Bucuvalas; W Cutfield; J Horn; M A Sperling; J E Heubi; B Campaigne; S D Chernausek
Journal:  J Pediatr       Date:  1990-09       Impact factor: 4.406

2.  Genome screening by searching for shared segments: mapping a gene for benign recurrent intrahepatic cholestasis.

Authors:  R H Houwen; S Baharloo; K Blankenship; P Raeymaekers; J Juyn; L A Sandkuijl; N B Freimer
Journal:  Nat Genet       Date:  1994-12       Impact factor: 38.330

3.  A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis.

Authors:  L N Bull; M J van Eijk; L Pawlikowska; J A DeYoung; J A Juijn; M Liao; L W Klomp; N Lomri; R Berger; B F Scharschmidt; A S Knisely; R H Houwen; N B Freimer
Journal:  Nat Genet       Date:  1998-03       Impact factor: 38.330

4.  Use of rifampin for severe pruritus in children with chronic cholestasis.

Authors:  B Yerushalmi; R J Sokol; M R Narkewicz; D Smith; F M Karrer
Journal:  J Pediatr Gastroenterol Nutr       Date:  1999-10       Impact factor: 2.839

5.  Phenobarbital effects in cholestatic liver diseases.

Authors:  J R Bloomer; J L Boyer
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

6.  Improvement of nutritional status in cholestatic children with supplemental nocturnal enteral nutrition.

Authors:  L A Moreno; F Gottrand; S Hoden; D Turck; G A Loeuille; J P Farriaux
Journal:  J Pediatr Gastroenterol Nutr       Date:  1991-02       Impact factor: 2.839

7.  A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis.

Authors:  S S Strautnieks; L N Bull; A S Knisely; S A Kocoshis; N Dahl; H Arnell; E Sokal; K Dahan; S Childs; V Ling; M S Tanner; A F Kagalwalla; A Németh; J Pawlowska; A Baker; G Mieli-Vergani; N B Freimer; R M Gardiner; R J Thompson
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

8.  Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass.

Authors:  P J Kaliciński; H Ismail; I Jankowska; A Kamiński; J Pawłowska; T Drewniak; M Markiewicz; M Szymczak
Journal:  Eur J Pediatr Surg       Date:  2003-10       Impact factor: 2.191

9.  Multicenter trial of d-alpha-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis.

Authors:  R J Sokol; N Butler-Simon; C Conner; J E Heubi; F R Sinatra; F J Suchy; M B Heyman; J Perrault; R J Rothbaum; J Levy
Journal:  Gastroenterology       Date:  1993-06       Impact factor: 22.682

10.  Intracranial hemorrhage due to vitamin K deficiency in breast-fed infants with cholestasis.

Authors:  J Bancroft; M B Cohen
Journal:  J Pediatr Gastroenterol Nutr       Date:  1993-01       Impact factor: 2.839

View more
  2 in total

Review 1.  Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations.

Authors:  Mortada H F El-Shabrawi; Naglaa M Kamal
Journal:  Paediatr Drugs       Date:  2011-12-01       Impact factor: 3.022

2.  Zinc level assessment in patients having Viral Cirrhosis.

Authors:  Lubna Kamani; Hafeezullah Shaikh
Journal:  Pak J Med Sci       Date:  2018 Mar-Apr       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.